Azelaic acid or hydroquinone? Compare the product and the purpose

First decide which problem is being discussed

A person with active acne and marks left after previous breakouts may need a different conversation from someone with established melasma. Someone with an isolated changing lesion may need an examination before either ingredient is considered. Those situations can look similar in a shopping search while having different treatment priorities.

AAD’s melasma treatment guidance includes hydroquinone and other possible topical options, including azelaic acid, within individualized care. It does not establish that any cosmetic product containing one of those names is an equivalent replacement for the clinician’s chosen prescription.

Tell the clinician whether the goal is controlling ongoing inflammation, addressing residual color, or treating diagnosed melasma. The post-acne marks guide explores why controlling the source of new marks may be just as important as fading older ones.

Approval attaches to a product and an indication

AZELEX is a prescription azelaic acid 20% cream. Its US label identifies mild-to-moderate inflammatory acne as its indication. That label does not say that the product is approved for melasma. A clinician’s use for another purpose is a separate question from the approved indication.

For hydroquinone, TRI-LUMA is an example of an approved finished combination with a specified facial melasma indication. It also contains tretinoin and a corticosteroid. Calling it simply “hydroquinone cream” loses information about both the product and its precautions. Our TRI-LUMA label review explains those distinctions.

Compounded preparations have a different regulatory status: FDA does not approve the finished compound before marketing. Likewise, an azelaic acid cosmetic on a retail shelf cannot borrow a prescription product’s approval merely because it shares an ingredient. Read the actual formulation, label, and intended purpose instead of treating approval as an ingredient-wide badge.

Different percentages are not a ranking scale

It is tempting to compare a 20% ingredient with a 4% ingredient as though both numbers describe the same thing. They do not. Azelaic acid and hydroquinone are different substances; the digits are concentrations within their respective preparations, not a common scale of clinical effectiveness or safety.

The surrounding formula also matters. A product may combine an ingredient with other active medicines or use a different vehicle. A clinician should evaluate that complete preparation and explain why it fits the treatment objective. Increasing concentration independently or substituting a competitor’s schedule cannot resolve those differences.

The same caution applies to marketing descriptions such as “gentle alternative,” “prescription strength,” or “maximum.” They may help position a product commercially, but they do not describe your skin’s response or replace evidence for the finished formulation. Ask what the term means in the actual product being offered.

An alternative can still cause unwanted effects

AZELEX labeling describes possible local irritation and reports of pigment loss, with a caution about monitoring color changes in darker complexions. “Not hydroquinone” therefore should not be read as “incapable of causing a problem.” Tell the clinician about prior reactions, current irritation, and other treatments before starting a different active.

Hydroquinone has its own precautions, including the risk of abnormal darkening known as ochronosis. FDA warns about unsafe skin-lightening products and makes the US prescription context clear. A switch between ingredients should be based on an assessment of the actual concern, rather than an assumption that one ingredient category has no risks.

Bring pregnancy, pregnancy plans, and breastfeeding into the discussion too. General online descriptions do not establish that a particular formula is suitable. The complete label and your clinical circumstances matter more than a broad claim that an ingredient is naturally occurring or widely used.

Ask what evidence supports the proposed use

When someone cites a study, look for the tested concentration, vehicle, diagnosis, comparison treatment, population, and follow-up. A study of a defined preparation does not automatically validate every serum, combination cream, or subscription product with the same ingredient. A before-and-after image without those details answers much less.

For this article, we verified product labeling and AAD guidance. We did not establish a direct clinical trial comparing the current CoreAge Rx Spot On finished formula with an azelaic acid product. Two candidate historical study pages could not be fully retrieved through the research tool, so we are not using their search snippets to announce a numerical winner.

The Spot On review describes its publicly listed hydroquinone, kojic acid, and niacinamide combination. Exact strengths were not confirmed on the reviewed public page. Its sponsored position here does not settle how it compares clinically with another preparation or whether it is appropriate for you.

The practical comparison belongs in the treatment plan

Useful questions include what the clinician expects to change, how tolerability will be reviewed, what would prompt an earlier check, and what the plan is if improvement is inadequate. Ask how any existing acne treatment or pigment product fits in. An answer limited to an ingredient’s reputation leaves the everyday decision unfinished.

Also confirm what is supplied, the written instructions, and the cost of follow-up. A formula can look attractive on paper while being difficult to tolerate or obtain consistently. Report those difficulties rather than improvising a new schedule or combining the products to get the advantages of both.

Finally, keep sun protection within the discussion. The tinted sunscreen guide explains the difference between UV labeling and visible-light considerations for melasma. Choosing between actives does not remove the need to address exposures and other factors that may be contributing to the pigmentation concern.